Novel leukocyte-depleted platelet-rich plasma-based skin equivalent as an in vitro model of chronic wounds: a preliminary study.
Cell Separation
Cells, Cultured
Fibroblasts
/ cytology
Gene Expression
/ drug effects
Interleukin-8
/ genetics
Keratinocytes
/ cytology
Leukocytes
Models, Biological
Platelet-Rich Plasma
Skin
/ injuries
Transforming Growth Factor alpha
/ genetics
Tumor Necrosis Factor-alpha
/ pharmacology
Wound Healing
Biomaterials
Inflammation
Platelet rich plasma
Skin equivalent
Wound healing
Journal
BMC molecular and cell biology
ISSN: 2661-8850
Titre abrégé: BMC Mol Cell Biol
Pays: England
ID NLM: 101741148
Informations de publication
Date de publication:
10 May 2021
10 May 2021
Historique:
received:
11
11
2020
accepted:
22
04
2021
entrez:
11
5
2021
pubmed:
12
5
2021
medline:
17
11
2021
Statut:
epublish
Résumé
Chronic leg ulcerations are associated with Haemoglobin disorders, Type2 Diabetes Mellitus, and long-term venous insufficiency, where poor perfusion and altered metabolism develop into a chronic inflammation that impairs wound closure. Skin equivalent organotypic cultures can be engineered in vitro to study skin biology and wound closure by modelling the specific cellular components of the skin. This study aimed to develop a novel bioactive platelet-rich plasma (PRP) leukocyte depleted scaffold to facilitate the study of common clinical skin wounds in patients with poor chronic skin perfusion and low leukocyte infiltration. A scratch assay was performed on the skin model to mimic two skin wound conditions, an untreated condition and a condition treated with recombinant tumour necrotic factor (rTNF) to imitate the stimulation of an inflammatory state. Gene expression of IL8 and TGFA was analysed in both conditions. Statistical analysis was done through ANOVA and paired student t-test. P < 0.05 was considered significant. A skin model that consisted of a leukocyte-depleted, platelet-rich plasma scaffold was setup with embedded fibroblasts as dermal equivalents and seeded keratinocytes as multi-layered epidermis. Gene expression levels of IL8 and TGFA were significantly different between the control and scratched conditions (p < 0.001 and p < 0.01 respectively), as well as between the control and treated conditions (p < 0.01 and p < 0.001 respectively). The scratch assay induced IL8 upregulation after 3 h (p < 0.05) which continued to increase up to day 1 (p < 0.05). On the other hand, the administration of TNF led to the downregulation of IL8 (p < 0.01), followed by an upregulation on day 2. IL8 gene expression decreased in the scratched condition after day 1 as the natural healing process took place and was lower than in the treated condition on day 8 (p < 0.05). Both untreated and treated conditions showed a downregulation of TGFA 3 h after scratch when compared with the control condition (p < 0.01). Administration of rTNF showed significant downregulation of TGFA after 24 h when compared with the control (p < 0.01) and treated conditions (p < 0.05). This study suggests that a leukocyte-depleted PRP-based skin equivalent can be a useful model for the in vitro study of chronic skin wounds related to poor skin perfusion.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic leg ulcerations are associated with Haemoglobin disorders, Type2 Diabetes Mellitus, and long-term venous insufficiency, where poor perfusion and altered metabolism develop into a chronic inflammation that impairs wound closure. Skin equivalent organotypic cultures can be engineered in vitro to study skin biology and wound closure by modelling the specific cellular components of the skin. This study aimed to develop a novel bioactive platelet-rich plasma (PRP) leukocyte depleted scaffold to facilitate the study of common clinical skin wounds in patients with poor chronic skin perfusion and low leukocyte infiltration. A scratch assay was performed on the skin model to mimic two skin wound conditions, an untreated condition and a condition treated with recombinant tumour necrotic factor (rTNF) to imitate the stimulation of an inflammatory state. Gene expression of IL8 and TGFA was analysed in both conditions. Statistical analysis was done through ANOVA and paired student t-test. P < 0.05 was considered significant.
RESULTS
RESULTS
A skin model that consisted of a leukocyte-depleted, platelet-rich plasma scaffold was setup with embedded fibroblasts as dermal equivalents and seeded keratinocytes as multi-layered epidermis. Gene expression levels of IL8 and TGFA were significantly different between the control and scratched conditions (p < 0.001 and p < 0.01 respectively), as well as between the control and treated conditions (p < 0.01 and p < 0.001 respectively). The scratch assay induced IL8 upregulation after 3 h (p < 0.05) which continued to increase up to day 1 (p < 0.05). On the other hand, the administration of TNF led to the downregulation of IL8 (p < 0.01), followed by an upregulation on day 2. IL8 gene expression decreased in the scratched condition after day 1 as the natural healing process took place and was lower than in the treated condition on day 8 (p < 0.05). Both untreated and treated conditions showed a downregulation of TGFA 3 h after scratch when compared with the control condition (p < 0.01). Administration of rTNF showed significant downregulation of TGFA after 24 h when compared with the control (p < 0.01) and treated conditions (p < 0.05).
CONCLUSION
CONCLUSIONS
This study suggests that a leukocyte-depleted PRP-based skin equivalent can be a useful model for the in vitro study of chronic skin wounds related to poor skin perfusion.
Identifiants
pubmed: 33971814
doi: 10.1186/s12860-021-00366-6
pii: 10.1186/s12860-021-00366-6
pmc: PMC8111747
doi:
Substances chimiques
Interleukin-8
0
Transforming Growth Factor alpha
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Subventions
Organisme : Foundation for Medical Service
ID : MDSRA01-01
Références
Am J Pathol. 2011 Jan;178(1):19-25
pubmed: 21224038
PLoS One. 2015 Mar 30;10(3):e0121713
pubmed: 25823008
Br J Dermatol. 2010 Aug;163(2):257-68
pubmed: 20394633
Cell. 2011 Jan 7;144(1):92-105
pubmed: 21215372
J Invest Dermatol. 1987 Nov;89(5):500-6
pubmed: 3668293
Cell Mol Biol. 1991;37(4):413-9
pubmed: 1934015
Wound Repair Regen. 1998 Jan-Feb;6(1):38-49
pubmed: 9776849
J Vasc Surg. 1997 Dec;26(6):994-9; discussion 999-1001
pubmed: 9423715
Am J Hematol. 2010 Oct;85(10):831-3
pubmed: 20872960
Eur J Immunol. 1994 Mar;24(3):646-50
pubmed: 8125134
Angiology. 1997 Jan;48(1):67-9
pubmed: 8995346
Br J Dermatol. 2006 Jun;154(6):1062-70
pubmed: 16704635
J Clin Invest. 2006 Jan;116(1):249-60
pubmed: 16395407
J Vasc Surg. 2001 Jun;33(6):1233-41
pubmed: 11389423
Clin Exp Dermatol. 2006 Nov;31(6):807-12
pubmed: 16981909
J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3
pubmed: 12244123
Wound Repair Regen. 1997 Oct-Dec;5(4):310-22
pubmed: 16984441
Stem Cells. 2014 Jun;32(6):1380-9
pubmed: 24497003
Front Biosci. 2004 Jan 01;9:283-9
pubmed: 14766366
N Engl J Med. 1996 Jun 27;334(26):1717-25
pubmed: 8637518
Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):E1451-2
pubmed: 24706908
Artif Organs. 2005 Oct;29(10):845-9
pubmed: 16185348
Plast Reconstr Surg. 1981 Mar;67(3):386-92
pubmed: 7232576
BMC Cell Biol. 2008 Sep 18;9:52
pubmed: 18799018
Indian J Plast Surg. 2012 May;45(2):220-8
pubmed: 23162220
J Immunol. 2010 Apr 1;184(7):3964-77
pubmed: 20176743
J Vasc Surg. 1998 Dec;28(6):1040-50
pubmed: 9845655
Annu Rev Immunol. 1992;10:411-52
pubmed: 1590993
Wound Repair Regen. 2009 Jan-Feb;17(1):1-18
pubmed: 19152646
Science. 1988 Aug 5;241(4866):708-12
pubmed: 3041594
Wound Repair Regen. 2008 Sep-Oct;16(5):585-601
pubmed: 19128254
J Invest Dermatol. 2007 Feb;127(2):331-41
pubmed: 17068485
Int J Hematol. 2008 Jul;88(1):7-15
pubmed: 18594779
Br J Haematol. 1993 Apr;83(4):669-71
pubmed: 8518184
Wound Repair Regen. 2004 May-Jun;12(3):359-67
pubmed: 15225215
Transfus Apher Sci. 2004 Apr;30(2):145-51
pubmed: 15062754
J Leukoc Biol. 2003 Apr;73(4):448-55
pubmed: 12660219
Int J Immunopharmacol. 1995 Feb;17(2):103-8
pubmed: 7657403
Science. 1997 Apr 4;276(5309):75-81
pubmed: 9082989
J Burn Care Rehabil. 2002 Mar-Apr;23(2):116-25
pubmed: 11882801
Curr Dermatol Rep. 2018;7(4):350-358
pubmed: 30524911
Am J Hematol. 2014 Jan;89(1):1-6
pubmed: 23963836
Br J Dermatol. 1997 Aug;137(2):188-94
pubmed: 9292065
Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):352-66
pubmed: 21241756